Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 352 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sham Injection Procedure Clear all
Completed Phase 2 Interventional Results available

A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD

NCT03953079
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Drug: GB-102, Aflibercept
Drug
Lead sponsor
Graybug Vision
Industry
Eligibility
50 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 30, 2026, 2:08 PM EDT
Recruiting Phase 4 Interventional

Paracervical Block for Pain Reduction in Saline Infusion Sonograms

NCT07048769
View directory record Official record
Conditions
Pain During Saline Infusion Sonogram
Interventions
Lidocaine, Sham paracervical block
Drug · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hartsdale, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Phase 3 Interventional

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

NCT00090623
View directory record Official record
Conditions
Macular Degeneration
Interventions
rhuFab V2 (ranibizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Phase II Combination Steroid and Anti-VEGF for Persistent DME

NCT01945866
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreal ranibizumab 0.3 mg, dexamethasone intravitreal implant, Sham injection
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
56
States / cities
Beverly Hills, California • Huntington Beach, California • Loma Linda, California + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 30, 2026, 2:08 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Stellate Ganglion Blockade in Post-Menopausal Women

NCT02907983
View directory record Official record
Conditions
Hot Flashes, Hot Flushes, Vasomotor Symptoms
Interventions
Stellate Ganglion Block Injection with Bupivicaine, Saline injection
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 70 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Effects of Pneumatic Vitreolysis on Vitreomacular Traction

NCT03647267
View directory record Official record
Conditions
Vitreomacular Traction
Interventions
Pneumatic Vitreolysis (C3F8 injection), Observation
Device · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Campbell, California • Huntington Beach, California • Mountain View, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

NCT02462928
View directory record Official record
Conditions
Macular Degeneration
Interventions
Abicipar Pegol, Ranibizumab, Sham Procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 30, 2026, 2:08 PM EDT
Terminated Phase 1Phase 2 Interventional

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

NCT00358423
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Pegaptanib Sodium, Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2008 · Synced Oct 30, 2026, 2:08 PM EDT
Active, not recruiting Not applicable Interventional

Stellate Ganglion Block for PTSD

NCT05169190
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
Stellate Ganglion Block, Sham Stellate Ganglion Block
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Long Beach, California • Tampa, Florida • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

NCT00168389
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Inglewood, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 30, 2026, 2:08 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Slit Face Trial Using Micro-injections of Transparent Hyaluronic Acid Gel for Rejuvenation of the Cheek

NCT02679924
View directory record Official record
Conditions
Problem of Aging
Interventions
Hyaluronic Acid filler, Sham Comparator
Device · Other
Lead sponsor
Isabella Guiha
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pain Control for Intrauterine Device Placement Using Paracervical Block

NCT02219308
View directory record Official record
Conditions
Pain Due to Intrauterine Contraceptive Device
Interventions
Paracervical Block (PCB), No Paracervical Block (Sham PCB)
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 30, 2026, 2:08 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Enhanced Recovery Strategies in Elective Breast Surgery

NCT03187080
View directory record Official record
Conditions
Pain, Acute, Nausea, Vomiting, Postoperative, Opioid Use, Satisfaction
Interventions
Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline, Enhanced recovery after breast surgery (ERABS) strategies, Sham paravertebral block using saline, Paravertebral block using local anesthetic
Procedure · Other · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Leukine (Sargramostim) for Parkinson's Disease

NCT01882010
View directory record Official record
Conditions
Parkinson's Disease
Interventions
sargramostim, placebo, Sham Comparator: Controls
Drug · Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
35 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00876863
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CERE-110: Adeno-Associated Virus injection Surgery, Placebo Surgery
Drug · Procedure
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
55 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using the Gate Control Theory of Pain to Decrease Pain During Trigger Finger Corticosteroid Injections

NCT06401473
View directory record Official record
Conditions
Trigger Finger, Pain
Interventions
Ipsilateral Scratch Task, Motor Distraction Task
Behavioral
Lead sponsor
Grand Canyon University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Gilbert, Arizona
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 30, 2026, 2:08 PM EDT
Terminated Phase 3 Interventional Results available

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

NCT02745119
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Lampalizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
122
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 30, 2026, 2:08 PM EDT
Recruiting Phase 2Phase 3 Interventional

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

NCT07592273
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Surabgene Lomparvovec, Sham, Topical Steroid, Artificial Tears
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
39
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Pectoral Blocks on Perioperative Pain in Gender Affirmation Top Surgery

NCT04474366
View directory record Official record
Conditions
Gender Dysphoria, Opioid Use, Pain, Postoperative
Interventions
Ropivacaine 0.2% Injectable Solution, Saline (0.9%)
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Semaglutide for Alcohol Use Disorder

NCT05520775
View directory record Official record
Conditions
Alcohol Use Disorder, Cigarette Smoking
Interventions
Semaglutide, Sham/placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

NCT03626636
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
Risuteganib, Sham
Drug · Other
Lead sponsor
Allegro Ophthalmics, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Gilbert, Arizona • Phoenix, Arizona • Beverly Hills, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 30, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

NCT01994291
View directory record Official record
Conditions
Macular Edema, Diabetic
Interventions
Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

Steroids Versus Gabapentin

NCT01495923
View directory record Official record
Conditions
Sciatica, Radiculopathy
Interventions
epidural steroid injection, Sham epidural steroid injection, Gabapentin, Placebo gabapentin
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
17 Years to 100 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 30, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment

NCT05730218
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment - Macula Off
Interventions
ONL1204 Ophthalmic Solution, Sham treatment
Drug
Lead sponsor
ONL Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 30, 2026, 2:08 PM EDT